
Danaher (DHR) Stock Forecast & Price Target
Danaher (DHR) Analyst Ratings
Bulls say
Danaher Corporation has demonstrated a strong performance in its life sciences and diagnostics sectors, with performance obligations increasing to $4.9 billion in the second quarter of 2025, reflecting robust demand. The company is also anticipating a growth ramp in the life sciences segment, projecting approximately 4.5% growth in the fourth quarter, supported by favorable market conditions and new product launches. Additionally, the respiratory segment appears well-positioned with expected revenues of $300-350 million in the third quarter and $450-500 million in the fourth quarter of 2025, indicating a resilient performance despite potential headwinds in other areas.
Bears say
Danaher is experiencing a decline in expected revenue recognition, with only 46% of 2Q25 obligations anticipated to convert into revenue within the next year, a decrease from 48% in the previous quarter. The company faces significant risks from geopolitical disruptions, foreign exchange fluctuations, and uncertainty regarding the recovery of high-growth end-markets, particularly in China. Additionally, the guidance for Biotechnology and Life Sciences revenue has fallen short of expectations for 3Q25, indicating potential challenges in sustaining growth moving forward.
This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares